Jonathan Villena‐Vargas

Author

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

J. Villena-Vargas, Jon Villena-Vargas, Jonathan Villena-Vargas, Jonathan Villena‐Vargas

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Weill Cornell Medicine Kagawa University NewYork–Presbyterian Hospital

About

Jonathan Villena‐Vargas is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	469
2	Health Sciences	2	2	272
3	Public Health	1	1	20
4	Emergency Medicine	1	1	16
5	Epidemiology	1	1	20

Jonathan Villena‐Vargas

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas, Journal of Clinical Investigation	2016	1K
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity Prasad S. Adusumilli, Leonid Cherkassky, Jonathan Villena‐Vargas, Science Translational Medicine	2014	552
Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa, The American Journal of Surgical Pathology Health SciencesAdvanced Lung DiseaseMedicineCancer RecurrenceIaslc/ats/ers Classification	2014	250
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma Stefan S. Kachala, Adam J. Bograd, Jonathan Villena‐Vargas, Clinical Cancer Research	2013	178
Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma Kyuichi Kadota, Yi‐Chen Yeh, Jonathan Villena‐Vargas, CHEST Journal Immune EvasionCancer ImmunosurveillanceOncologyMedicineLung Adenocarcinoma	2015	79
National trends and perioperative outcomes of robotic resection of thymic tumours in the United States: a propensity matching comparison with open and video-assisted thoracoscopic approaches† Mohamed Kamel, Jonathan Villena‐Vargas, Mohamed Rahouma, European Journal of Cardio-Thoracic Surgery	2019	50
Percutaneous and Open Tracheostomy in Patients with COVID-19 Sallie Long, Alexander Chern, Noah Z. Feit, Annals of Surgery	2020	46
Imaging CAR T-cell kinetics in solid tumors: Translational implications Matthew S. Skovgard, Hocine R. Hocine, Jasmeen Saini, Molecular Therapy — Oncolytics	2021	41
Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration Kyuichi Kadota, Takashi Eguchi, Jonathan Villena‐Vargas, Oncotarget	2015	25
Extent of Resection Influences Survival in Early-Stage Lung Cancer With Occult Nodal Disease Nathan Mynard, Abu Nasar, Mohamed Rahouma, The Annals of Thoracic Surgery Surgical OncologyEarly-stage Lung CancerMedicinePathologyBronchial Neoplasm	2022	22

Page 1